Objective To explore the analysis on curative effects of icotinib in targeted treatment of advanced non-small cell lung cancer. Methods 86 patients with advanced non-small cell lung cancer who were treated in department of oncology in our hospital from January 2017 to January 2018 were randomly divided into two groups. The control group was treated with chemotherapy while the observation group was treated with icotinib on basis of the control group.The short-term curative effects,symptom relief time,time of disease progression,mean survival time,incidence of adverse reactions and correlation between curative effects and clinical features were compared between the two groups. Results The objective relief rate and disease control rate of the observation group were respectively 48.84% and 86.05%,which were significantly higher than those of the control group (27.91% and 69.77%,P < 0.05).The symptoms relief time in the observation group was significantly shorter than that in the control group,while the time of disease progression and mean survival time were significantly longer than those in the control group (P < 0.05).The incidence of adverse reactions such as rash,diarrhea,gastrointestinal discomfort and slightly increase of transaminase in the observation group was not significantly different from that in the control group (P > 0.05).However,the incidence of radioactive pneumonia in the observation group was significantly lower than that in the control group (P < 0.05). Conclusion Icotinib in targeted treatment of advanced non-small cell lung cancer has significant curative effects and it can effectively improve the late curative effects.The incidence of adverse reactions can be controlled and patients are well tolerated.It provides a new selection for clinical treatment of advanced nonsmall cell lung cancer.
China Medicine And Pharmacy
Advanced non-small cell lung cancer
Short-term curative effects
Toxic side effects